Expression of costimulatory TNFR2 induces resistance of CD4 +FoxP3- conventional T cells to suppression by CD4 +FoxP3+ regulatory T cells

Journal of Immunology

Volumn 185, Issue 1, 2010, Pages 174-182

  Chen, Xin ^a   Hamano, Ryoko ^b,c   Subleski, Jeffrey J ^b   Hurwitz, Arthur A ^b   Howard, O M Zack ^b   Oppenheim, Joost J ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RECEPTOR 2; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; LEWIS CARCINOMA; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR IMMUNOLOGY; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CLONAL ANERGY; COCULTURE; COMPARATIVE STUDY; CYTOLOGY; EXPERIMENTAL NEOPLASM; GENE TARGETING; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOMA, LEWIS LUNG; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CLONAL ANERGY; COCULTURE TECHNIQUES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE KNOCK-IN TECHNIQUES; IMMUNITY, INNATE; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; T-LYMPHOCYTES, REGULATORY;

EID: 77956201549     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903548     Document Type: Article

References (38)

1. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133: 775-787.
2. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307.
3. Yu, P., Y. Lee, W. Liu, T. Krausz, A. Chong, H. Schreiber, and Y. X. Fu. 2005. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201: 779-791.
4. Piconese, S., B. Valzasina, and M. P. Colombo. 2008. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205: 825-839.
5. Chaput, N., G. Darrasse-Jèze, A. S. Bergot, C. Cordier, S. Ngo-Abdalla, D. Klatzmann, and O. Azogui. 2007. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J. Immunol. 179: 4969-4978.
6. Hung, K., R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky. 1998. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188: 2357-2368.
7. Kim, E. Y., J. J. Priatel, S. J. Teh, and H. S. Teh. 2006. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J. Immunol. 176: 1026-1035.
8. Kim, E. Y., and H. S. Teh. 2001. TNF type 2 receptor (p75) lowers the threshold of T cell activation. J. Immunol. 167: 6812-6820.
9. Kim, E. Y., and H. S. Teh. 2004. Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J. Immunol. 173: 4500-4509.
10. Chen, X., J. J. Subleski, H. Kopf, O. M. Howard, D. N. Männel, and J. J. Oppenheim. 2008. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J. Immunol. 180: 6467-6471.
11. Balkwill, F. 2009. Tumour necrosis factor and cancer. Nat. Rev. Cancer 9: 361-371.
12. van Mierlo, G. J., H. U. Scherer, M. Hameetman, M. E. Morgan, R. Flierman, T. W. Huizinga, and R. E. Toes. 2008. Cutting edge: TNFR-shedding by CD4+ CD25+ regulatory T cells inhibits the induction of inflammatory mediators. J. Immunol. 180: 2747-2751.
13. Chen, X., J. J. Subleski, R. Hamano, O. M. Howard, R. H. Wiltrout, and J. J. Oppenheim. 2010. Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. Eur. J. Immunol. 40: 1099-1106.
14. Chen, X., M. Bäumel, D. N. Männel, O. M. Howard, and J. J. Oppenheim. 2007. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J. Immunol. 179: 154-161.
15. Zheng, Y., and A. Y. Rudensky. 2007. Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 8: 457-462.
16. Scholzen, T., and J. Gerdes. 2000. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 182: 311-322.
17. van der Most, R. G., A. J. Currie, S. Mahendran, A. Prosser, A. Darabi, B. W. Robinson, A. K. Nowak, and R. A. Lake. 2008. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol. Immunother. 58: 1219-1228.
18. Chen, X., J. J. Oppenheim, and O. M. Howard. 2005. BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL/6 mice. J. Leukoc. Biol. 78: 114-121.
19. Fisson, S., G. Darrasse-Jèze, E. Litvinova, F. Septier, D. Klatzmann, R. Liblau, and B. L. Salomon. 2003. Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J. Exp. Med. 198: 737-746.
20. Carpentier, I., B. Coornaert, and R. Beyaert. 2004. Function and regulation of tumor necrosis factor type 2. Curr. Med. Chem. 11: 2205-2212.
21. Aggarwal, B. B. 2003. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3: 745-756.
22. Tartaglia, L. A., D. V. Goeddel, C. Reynolds, I. S. Figari, R. F. Weber, B. M. Fendly, and M. A. Palladino, Jr. 1993. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J. Immunol. 151: 4637-4641.
23. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
24. Liu, V. C., L. Y. Wong, T. Jang, A. H. Shah, I. Park, X. Yang, Q. Zhang, S. Lonning, B. A. Teicher, and C. Lee. 2007. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J. Immunol. 178: 2883-2892.
25. Wang, L., K. Pino-Lagos, V. C. de Vries, I. Guleria, M. H. Sayegh, and R. J. Noelle. 2008. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc. Natl. Acad. Sci. USA 105: 9331-9336.
26. Zhou, G., and H. I. Levitsky. 2007. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J. Immunol. 178: 2155-2162.
27. Ghiringhelli, F., P. E. Puig, S. Roux, A. Parcellier, E. Schmitt, E. Solary, G. Kroemer, F. Martin, B. Chauffert, and L. Zitvogel. 2005. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+ CD25+ regulatory T cell proliferation. J. Exp. Med. 202: 919-929.
28. Chen, W., W. Jin, N. Hardegen, K. J. Lei, L. Li, N. Marinos, G. McGrady, and S. M. Wahl. 2003. Conversion of peripheral CD4+CD25- naive T cells to CD4+ CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198: 1875-1886.
29. Li, M. O., Y. Y. Wan, S. Sanjabi, A. K. Robertson, and R. A. Flavell. 2006. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24: 99-146.
30. Oppenheim, J. J. 2007. IL-2: more than a T cell growth factor. J. Immunol. 179: 1413-1414.
31. Piancatelli, D., P. Romano, P. Sebastiani, D. Adorno, and C. U. Casciani. 1999. Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression. J. Immunother. 22: 25-32.
32. Knerer, B., W. Hulla, H. Martinek, M. Formanek, A. Temmel, and J. Kornfehl. 1996. IL-1 and TNF-alpha but no IL-2 expression is found in squamous cell carcinomas of the head and neck by RT-PCR. Acta Otolaryngol. 116: 132-136.
33. Zuckerberg, A. L., L. I. Goldberg, and H. M. Lederman. 1994. Effects of hypoxia on interleukin-2 mRNA expression by T lymphocytes. Crit. Care Med. 22: 197-203.
34. Yang, J., M. O. Brook, M. Carvalho-Gaspar, J. Zhang, H. E. Ramon, M. H. Sayegh, K. J. Wood, L. A. Turka, and N. D. Jones. 2007. Allograft rejection mediated by memory T cells is resistant to regulation. Proc. Natl. Acad. Sci. USA 104: 19954-19959.
35. Sabbagh, L., L. M. Snell, and T. H. Watts. 2007. TNF family ligands define niches for T cell memory. Trends Immunol. 28: 333-339.
36. Rauert, H., A. Wicovsky, N. Müller, D. Siegmund, V. Spindler, J. Waschke, C. Kneitz, and H. Wajant. 2010. Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J. Biol. Chem. 285: 7394-7404.
37. Whiteside, T. L. 1999. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol. Immunother. 48: 346-352.
38. Feldmann, M. 2002. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2: 364-371.